Lemuel A. Iii Moyé

Lemuel A. Iii Moyé's AcademicInfluence.com Rankings

Lemuel A. Iii Moyé

Medical

#2648

World Rank

#3079

Historical Rank

Cardiology

#249

World Rank

#255

Historical Rank

Public Health

#401

World Rank

#414

Historical Rank

Epidemiology

#494

World Rank

#516

Historical Rank

medical Degrees

Lemuel A. Iii Moyé

Philosophy

#7610

World Rank

#10848

Historical Rank

Logic

#4656

World Rank

#5975

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Lemuel A. Iii Moyé Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Lemuel A. Iii Moyé's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. (1996) (6618)
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. (1992) (5870)
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients (2000) (1551)
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. (1998) (1476)
Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. (2004) (1029)
Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. (1998) (1015)
Quantitative Two-Dimensional Echocardiographic Measurements are Major Predictors of Adverse Cardiovascular Events After Acute Myocardial Infarction: The Protective Effect of Captopril (1994) (847)
Sex differences in the management of coronary artery disease. Survival and Ventricular Enlargement Investigators. (1991) (767)
Clinical significance of mitral regurgitation after acute myocardial infarction. Survival and Ventricular Enlargement Investigators. (1997) (668)
Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. (1998) (632)
Relation Between Red Blood Cell Distribution Width and Cardiovascular Event Rate in People With Coronary Disease (2008) (612)
Ventricular dysfunction and the risk of stroke after myocardial infarction. (1997) (579)
Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement. (1997) (533)
Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. (1997) (501)
VLDL, Apolipoproteins B, CIII, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial (2000) (478)
Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. (2012) (453)
The cardiac arrhythmia suppression trial. Casting suppression in a different light. (1995) (450)
Effect of Pravastatin on Cardiovascular Events in Older Patients with Myocardial Infarction and Cholesterol Levels in the Average Range: Results of the Cholesterol and Recurrent Events (CARE) Trial (1998) (448)
Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. (1999) (432)
Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. (2002) (424)
Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. (2011) (411)
Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. (2012) (399)
Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. (1998) (381)
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials (2019) (377)
Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. (1994) (348)
Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. (2003) (321)
A comparison of management patterns after acute myocardial infarction in Canada and the United States. The SAVE investigators. (1993) (314)
Excess stroke in Mexican Americans compared with non-Hispanic Whites: the Brain Attack Surveillance in Corpus Christi Project. (2004) (311)
Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. (2003) (300)
Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. (1994) (296)
Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. (1994) (278)
Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. (2015) (274)
N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. (1994) (260)
Differences in the Composition of Preterm and Term Human Milk during Early Lactation (1982) (242)
Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. (1998) (232)
Effect of infarct artery patency on prognosis after acute myocardial infarction. The Survival and Ventricular Enlargement Investigators. (1995) (215)
Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. (1997) (214)
Constraint-Induced Movement Therapy During Early Stroke Rehabilitation (2007) (207)
Chronic Kidney Disease, Cardiovascular Risk, and Response to Angiotensin-Converting Enzyme Inhibition After Myocardial Infarction: The Survival And Ventricular Enlargement (SAVE) Study (2004) (193)
Simultaneous vs sequential counseling for multiple behavior change. (2007) (186)
Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. (2006) (181)
LDL Containing Apolipoprotein CIII Is an Independent Risk Factor for Coronary Events in Diabetic Patients (2003) (168)
Activation of neurohumoral systems in postinfarction left ventricular dysfunction. (1993) (166)
Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial (2008) (152)
Low-density lipoprotein size, pravastatin treatment, and coronary events. (2001) (145)
Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. (1996) (138)
Mesenchymal Precursor Cells as Adjunctive Therapy in Recipients of Contemporary Left Ventricular Assist Devices (2014) (137)
Selection Bias in the Use of Thrombolytic Therapy in Acute Myocardial Infarction (1991) (133)
Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. (1997) (130)
Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial. (2009) (130)
Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE) (1991) (129)
Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators. (1995) (129)
An initial strategy of intensive medical therapy is comparable to that of coronary revascularization for suppression of scintigraphic ischemia in high-risk but stable survivors of acute myocardial infarction. (2006) (128)
Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. (1998) (124)
Coping, life attitudes, and immune responses to imagery and group support after breast cancer treatment. (1997) (116)
Risk of developing life-threatening ventricular arrhythmia associated with tefenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine. (1994) (114)
A multinational study to establish the value of early adenosine technetium-99m sestamibi myocardial perfusion imaging in identifying a low-risk group for early hospital discharge after acute myocardial infarction. (2006) (114)
Uniformity of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study. (1994) (110)
A Randomized, Controlled Trial to Teach Middle School Children to Recognize Stroke and Call 911: The Kids Identifying and Defeating Stroke Project (2007) (109)
Activation of neurohumoral systems following acute myocardial infarction. (1991) (108)
Coley toxins immunotherapy: a retrospective review. (1999) (104)
Comparison of active and passive surveillance for cerebrovascular disease: The Brain Attack Surveillance in Corpus Christi (BASIC) Project. (2002) (103)
Concise Review: Review and Perspective of Cell Dosage and Routes of Administration From Preclinical and Clinical Studies of Stem Cell Therapy for Heart Disease (2015) (102)
Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. (1999) (101)
Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events. (1999) (85)
Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Levels Subgroup Analyses in the Cholesterol And Recurrent Events (CARE) Trial Clinical Investigation and Reports (1998) (85)
Risk of all-cause mortality, recurrent myocardial infarction, and heart failure hospitalization associated with smoking status following myocardial infarction with left ventricular dysfunction. (2010) (85)
Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction. (2009) (84)
Access to Care, Acculturation, and Risk Factors for Stroke in Mexican Americans: The Brain Attack Surveillance in Corpus Christi (BASIC) Project (2003) (81)
The Cardiac Arrhythmia Suppression Trial: background, interim results and implications. (1990) (80)
Alcohol consumption and prognosis in patients with left ventricular systolic dysfunction after a myocardial infarction. (2004) (79)
Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration. (1995) (79)
Barriers to Acute Stroke Therapy and Stroke Prevention in Mexican Americans (2001) (78)
Argatroban tPA stroke study: study design and results in the first treated cohort. (2006) (73)
Designing multi-ethnic stroke studies: the Brain Attack Surveillance in Corpus Christi (BASIC) project. (2004) (66)
Rationale, design and baseline characteristics of the survival and ventricular enlargement trial (1991) (65)
Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit+ Cardiac Stem Cells As Regenerative Therapy for Heart Failure) (2018) (65)
Alpha calculus in clinical trials: considerations and commentary for the new millennium. (2000) (64)
Multiple Analyses in Clinical Trials: Fundamentals for Investigators (2003) (64)
Environmental contamination of continuous drip feedings. (1979) (63)
P-value interpretation and alpha allocation in clinical trials. (1998) (62)
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. (2010) (61)
High reproducibility of myocardial perfusion defects in patients undergoing serial exercise thallium-201 tomography. (1995) (60)
Left ventricular end-diastolic pressure and risk of subsequent heart failure in patients following an acute myocardial infarction. (2007) (57)
Autism spectrum disorder prevalence and proximity to industrial facilities releasing arsenic, lead or mercury. (2015) (57)
A Phase II study of autologous mesenchymal stromal cells and c‐kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT‐HF trial (2021) (53)
Transdermal nitroglycerin patch therapy improves left ventricular function and prevents remodeling after acute myocardial infarction: results of a multicenter prospective randomized, double-blind, placebo-controlled trial. (1998) (53)
End-point interpretation in clinical trials: the case for discipline. (1999) (52)
The platelet PlA2 and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction (2001) (52)
Detailed Analysis of Bone Marrow From Patients With Ischemic Heart Disease and Left Ventricular Dysfunction: BM CD34, CD11b, and Clonogenic Capacity as Biomarkers for Clinical Outcomes (2014) (52)
Carvedilol and the Food and Drug Administration approval process: an introduction. (1999) (52)
Hypertriglyceridemia but not diabetes status is associated with VLDL containing apolipoprotein CIII in patients with coronary heart disease. (2003) (51)
Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial. (2015) (51)
Bone marrow mononuclear cell therapy for acute myocardial infarction: a perspective from the cardiovascular cell therapy research network. (2014) (51)
Ischemic stroke subtypes among Mexican Americans and non-Hispanic whites (2004) (51)
Autism spectrum disorder prevalence and associations with air concentrations of lead, mercury, and arsenic (2016) (50)
Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators. (1991) (49)
Therapeutic benefit. Aspirin revisited in light of the introduction of clopidogrel. (1999) (47)
Ethnic differences in stroke recurrence (2006) (47)
Phase II clinical research design in cardiology: learning the right lessons too well: observations and recommendations from the Cardiovascular Cell Therapy Research Network (CCTRN). (2013) (46)
Development of a Network to Test Strategies in Cardiovascular Cell Delivery: The NHLBI-sponsored Cardiovascular Cell Therapy Research Network (CCTRN) (2010) (46)
Safety and Efficacy of Succimer in Toddlers with Blood Lead Levels of 20–44 μg/dL (2000) (46)
Ventricular Remodeling Does Not Accompany the Development of Heart Failure in Diabetic Patients After Myocardial Infarction (2002) (43)
TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function Final 2-Year Analysis (2017) (42)
Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design. (2010) (42)
Expressive writing as a presurgical stress management intervention for breast cancer patients. (2008) (41)
Analysis of a clinical trial involving a combined mortality and adherence dependent interval censored endpoint. (1992) (40)
Evaluating minimal important differences for the FACT-Melanoma quality of life questionnaire. (2009) (40)
The theory of runs with applications to drought prediction (1988) (40)
Criteria for the accurate interpretation of changes in left ventricular ejection fraction and cardiac volumes as assessed by rest and exercise gated radionuclide angiography. (1991) (40)
Autism spectrum disorder reporting in lower socioeconomic neighborhoods (2017) (40)
Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels. (1995) (39)
Meta-Analyses of Human Cell-Based Cardiac Regeneration Therapies: Controversies in Meta-Analyses Results on Cardiac Cell-Based Regenerative Studies. (2016) (38)
The relative efficacy of four methods of human milk expression. (1982) (38)
Multicenter cell processing for cardiovascular regenerative medicine applications: the Cardiovascular Cell Therapy Research Network (CCTRN) experience. (2010) (37)
Multiple Analyses in Clinical Trials (2004) (36)
Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells). (2017) (36)
Trials within trials: confirmatory subgroup analyses in controlled clinical experiments. (2001) (32)
Bayesians in clinical trials: Asleep at the switch (2008) (32)
Amino acid composition of preterm and term breast milk during early lactation. (1983) (31)
Stroke burden in Mexican Americans: the impact of mortality following stroke. (2006) (31)
Identification of Bone Marrow Cell Subpopulations Associated with Improved Functional Outcomes in Patients with Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial (2016) (29)
Rationale and design for PACE: patients with intermittent claudication injected with ALDH bright cells. (2014) (29)
Exploring the minimal dose of amiodarone with antiarrhythmic and hemodynamic activity. (1994) (28)
Statistical Methods for Cardiovascular Researchers. (2016) (27)
Additive Beneficial Effects of Beta-Blockers to Angiotensin-Converting Enzyme Inhibitors in the Survival and Ventricular Enlargement (SAVE) Study fn1fn1This study was supported by a University-Industry grant from the Medical Research Council, Ottawa, Ontario, Canada and Bristol Myers Squibb, Montrea (1997) (27)
Research methodology in psychoneuroimmunology: rationale and design of the IMAGES-P clinical trial. (1995) (27)
Defending the Rationale for the Two-Tailed Test in Clinical Research (2002) (25)
Predicting duration of stay in a pediatric intensive care unit: A Markovian approach (2000) (25)
Circulating Biomarkers to Identify Responders in Cardiac Cell therapy (2017) (24)
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials (2022) (23)
Effect of Two Cancer Chemotherapeutic Agents on the Antibacterial Activity of Three Antimicrobial Agents (1978) (23)
Statistical Reasoning in Medicine (2000) (22)
Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationale. (2011) (22)
Cell tracking and the development of cell-based therapies: a view from the Cardiovascular Cell Therapy Research Network. (2012) (22)
Mathematical Statistics With Applications (2005) (21)
Conclusions and implications of the systolic hypertension in the elderly program. (1993) (21)
Quantification of myocardial segmental function in acute and chronic ischemic heart disease and implications for cardiovascular cell therapy trials: a review from the NHLBI-Cardiovascular Cell Therapy Research Network. (2011) (21)
Improving efficiency of stroke research: the Brain Attack Surveillance in Corpus Christi study. (2003) (21)
A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure: the ACCLAIM trial rationale and design. (2007) (20)
The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. (2001) (20)
Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients (2020) (19)
Does body fatness modify the effect of dietary cholesterol on serum cholesterol? Results from the Chicago Western Electric Study. (1993) (18)
Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement. (1998) (18)
Consistently Inconsistent-Bone Marrow Mononuclear Stem Cell Therapy Following Acute Myocardial Infarction: A Decade Later. (2016) (18)
Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) Trial (2018) (18)
Prognostic use of echocardiography 1 year after a myocardial infarction. (2005) (17)
Evaluation of ethnic minorities and gender effects in clinical trials: opportunities lost and rediscovered. (2001) (17)
Chemotherapy and Survival for Patients With Multiple Myeloma: Findings From a Large Nationwide and Population-Based Cohort (2007) (17)
Brownian motion and long-term clinical trial recruitment (2001) (16)
Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial. (2016) (16)
Identification of cardiovascular risk factors associated with bone marrow cell subsets in patients with STEMI: a biorepository evaluation from the CCTRN TIME and LateTIME clinical trials (2015) (15)
Predictions of drought length extreme order statistics using run theory (1995) (15)
DAMASCENE and Meta-Ecological Research: A Bridge Too Far. (2014) (15)
Baseline assessment and comparison of arterial anatomy, hyperemic flow, and skeletal muscle perfusion in peripheral artery disease: The Cardiovascular Cell Therapy Research Network “Patients with Intermittent Claudication Injected with ALDH Bright Cells” (CCTRN PACE) study (2017) (13)
The Cardiac Arrhythmia Suppression Trial: Implications for Antiarrhythmic Drug Development (1990) (13)
Kids Identifying and Defeating Stroke (KIDS): Development and Implementation of a Multiethnic Health Education Intervention to Increase Stroke Awareness Among Middle School Students and Their Parents (2010) (13)
Effect of pravastatin on apolipoproteins B and C-III in very-low-density lipoproteins and low-density lipoproteins. (2002) (11)
Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). (1992) (11)
Statistical monitoring clinical trials : fundamentals for investigators (2005) (11)
Kids Identifying and Defeating Stroke (KIDS): design of a school-based intervention to improve stroke awareness. (2007) (10)
Sample size for biomarker studies: more subjects or more measurements per subject? (2003) (10)
Meta-Analyses of Human Cell-Based Cardiac Regeneration TherapiesResponse to Gyöngyösi, Wojakowski, Navarese, Moyé, and the ACCRUE Investigators: Controversies in Meta-Analyses Results on Cardiac Cell-Based Regenerative Studies (2016) (9)
Disciplined analyses in clinical trials: the dark heart of the matter (2008) (9)
Detailed Analysis of Bone Marrow From Patients With Ischemic Heart Disease and Left Ventricular DysfunctionNovelty and Significance (2014) (9)
Does Clinical-CT ‘Mismatch’ Predict Early Response to Treatment with Recombinant Tissue Plasminogen Activator? (2006) (9)
A Critical Analysis of Clinical Outcomes Reported in Stem Cell Trials for Acute Myocardial Infarction: Some Thoughts for Design of Future Trials (2013) (9)
Random Research (2001) (8)
Bone marrow-derived cell therapy after myocardial infarction. (2013) (8)
An Introduction to Queueing Theory: Modeling and Analysis in Applications (2006) (8)
Should linen in newborn intensive care units be autoclaved? (1981) (8)
The fragility of cardiovascular clinical trial results. (2002) (7)
Rationale, design and baseline characteristics of the survival and ventricular enlargement trial. SAVE Investigators. (1991) (6)
Central laboratory sampling plans and quality control in clinical trials. (1991) (6)
Measurement of Plasma Lipids in Patients Admitted With Acute Myocardial Infarction or Unstable Angina Pectoris (2001) (6)
Modeling the Pharmacologic Treatment of Hypertension (1982) (6)
Combining Censored and Uncensored Data in a U-Statistic: Design and Sample Size Implications for Cell Therapy Research (2011) (6)
Design of a randomized, placebo-controlled multicenter trial on the long-term effects of intermittent transdermal nitroglycerin on left ventricular remodeling after acute myocardial infarction. Transdermal Nitroglycerin Investigators Group. (1998) (6)
Controlled, Pilot Trial Evaluating the Safety and Effect of Administration of Bone Marrow Mononuclear Cells 2 to 3 Weeks after Acute Myocardial Infarction (2010) (6)
Physical working capacity after acute myocardial infarction in patients with low ejection fraction and effect of captopril. (1995) (6)
Elementary Bayesian Biostatistics (2020) (6)
Nutritional outcome of 207 very low-birth-weight infants in an intensive care unit. (1982) (6)
Systolic Hypertension of the Elderly Program (SHEP). Part 9: Behavioral characteristics. (1991) (6)
Factors affecting the turnaround time for manufacturing, testing, and release of cellular therapy products prepared at multiple sites in support of multicenter cardiovascular regenerative medicine protocols: a Cardiovascular Cell Therapy Research Network (CCTRN) study (2012) (6)
Adaptive group‐sequential design with population enrichment in phase 3 randomized controlled trials with two binary co‐primary endpoints (2019) (6)
Cell therapy and satellite centers: the Cardiovascular Cell Therapy Research Network experience. (2011) (5)
Selecting screening criteria for clinical trials: an example from the Systolic Hypertension in the Elderly Program. (1999) (5)
Oversight and management of a cell therapy clinical trial network: experience and lessons learned. (2011) (5)
Dependence, hyper-dependence and hypothesis testing in clinical trials. (2007) (5)
Carvedilol in patients with chronic heart failure. (1996) (5)
Difference Equations with Public Health Applications (2007) (4)
Sizing clinical trials with variable endpoint event rates. (1997) (4)
Clinical trials in cardiology: pinnacle or inflection point? (2014) (4)
Evaluation of a system for continuous neonatal blood pressure monitoring. (1982) (4)
Growth outcome of the very low-birth-weight infant at one year. (1983) (4)
What can we do about exploratory analyses in clinical trials? (2015) (4)
Overcoming Anxiety, Stress and Panic A Five Areas Approach (2012) (4)
Implementation of Cardovascular Cell Therapy Network trials: challenges, innovation and lessons learned from experience in the CCTRN (2013) (4)
Clinical trial minority recruitment: still an unmet need. (2002) (4)
Bone MarrowDerived Cell Therapy After Myocardial Infarction (2013) (3)
Captopril for left ventricular dysfunction after myocardial infarction reduced mortality and morbidity (1993) (3)
Liberation From the P Value's Tyranny. (2018) (3)
Association between High Endocardial Unipolar Voltage and Improved Left Ventricular Function in Patients with Ischemic Cardiomyopathy. (2016) (3)
The Basis of Statistical Reasoning in Medicine (2006) (3)
Impaired therapeutic efficacy of bone marrow cells from post-myocardial infarction patients in the TIME and LateTIME clinical trials (2019) (3)
Baseline Assessment and Comparison of Arterial Anatomy , Hyperemic Flow and Skeletal Muscle Perfusion in Peripheral Artery Disease : The CCTRN PACE Study (2016) (2)
21 The Multiple Comparison Issue in Health Care Research (2007) (2)
TCT-823 Results from LateTIME: A Randomized, Placebo Controlled Trial of Intracoronary Stem Cell Delivery Two to Three Weeks Following Acute Myocardial Infarction from the Cardiovascular Cell Therapy Research Network (2013) (2)
Part 9: Behavioral Characteristics (1991) (2)
Rudiments of subgroup analyses. (2012) (2)
A Scoring System for Ascertainment of Incident Stroke; the Risk Index Score (RISc) (2006) (2)
Hypothesis testing complexity in the name of ethics: response to commentary. (2002) (2)
Bayesian P Values (2000) (1)
Cardiac Arrhythmia Suppression Trial (CAST) (2008) (1)
Development of ekg abnormalities in non-insulin dependent diabetes mellitus (NIDDM): Incidence and risk factors (1984) (1)
A Prediction Model for Outpatient Visits and Cash Flow: Developments in Prospective Run Theory (1990) (1)
DiscussionThe theory of runs with applications to drought prediction — reply (1989) (1)
The perils of nonprospectively planned research. Part 1: drawing conclulsions from sample-based research. (2001) (1)
Abstract 5636: Time From Onset of Acute Anterior Myocardial Infarction Negatively Influences Bone Marrow Cell Function: Preliminary Data From the NHLBI CCTRN Ancillary Studies (2009) (1)
Underestimation of the valvulopathy effect of fenfluramine. (2000) (1)
Abstract 15644: The NHLBI and Cardiovascular Cell Therapy Research Network (CCTRN) TIME Trial: Two-Year Results (2014) (1)
Appetite-suppressant drugs and valvular heart disease. (1999) (1)
Decision rules for predicting future lipid values in screening for a cholesterol reduction clinical trial. (1996) (1)
P Values and Multiple Endpoints I: Pernicious Abstractions? (2000) (0)
Simultaneous population enrichment and endpoint selection in phase 3 randomized controlled trials: An adaptive group sequential design with two binary alternative primary endpoints (2023) (0)
Bayesian Analysis: Posterior P -values (2006) (0)
P values and Multiple Endpoints II: Noxious Placebos in the Population (2000) (0)
Sample Size Re-Estimation Based on Two-Stage Analysis of Variance: Interim Analysis of Clinical Trials (2012) (0)
Reductions in funding for medical research. (2013) (0)
BONE MARROW EPC FUNCTION RELATIVE TO TIME OF COLLECTION AFTER ACUTE MYOCARDIAL INFARCTION (2010) (0)
Abstract 6131: Regadenoson Induces Perfusion Defects of Comparable Extent and Severity as Adenosine: A Quantitative Analysis from the ADVANCE 2 Trial (2008) (0)
Prologue: Aliis exterendum (2006) (0)
List of Contributors (2019) (0)
The association of HSV 1 and 2 with atherosclerosis defined by CRP level (2008) (0)
Conclusions: Good Servants but Bad Masters (2000) (0)
Comprar Elementary Bayesian Biostatistics | Lemuel A. Moye | 9781584887249 | Informa Healthcare (2007) (0)
Abstract 6102: Integration of Non-Contrast Cardiac Computed Tomography and Stress Myocardial Perfusion Imaging in the Emergency Department: Identifying Which Patients with Chest Pain Can be Safely Discharged Home (2008) (0)
Trial Levels : Subgroup Analyses in the Cholesterol And Recurrent Events ( CARE ) Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and (1998) (0)
The perils of nonprospectively planned research. Part 2: Guidelines for reviewing the results of sample-based research. (2001) (0)
Statistical Interpretation of the Utility and Value of a Biomarker (2019) (0)
Subject Index Vol. 22, 2006 (2006) (0)
The History and Future of the Cardiovascular Cell Therapy Research Network (2016) (0)
Contents Vol. 22, 2006 (2006) (0)
Abstract 16354: Improved Myocardial Function in Patients with Chronic Ischemic Heart Disease Treated with Transendocardial Delivery of Bone Marrow Mononuclear Cells Depends Upon Input Cell Phenotype and Function (2012) (0)
Abstract 722: High Reproducibility of Serial Adenosine Single Photon Tomography Myocardial Perfusion Studies: A Quantitative Analysis from the ADVANCE 2 Study (2008) (0)
“Sir, you are unethical!” One-tailed vs. Two-tailed Testing (2000) (0)
“Your Searchlight’s Not On!” Power and P Values (2000) (0)
P -values, Power, and Efficacy (2006) (0)
WIRKUNG VON CAPTOPRIL AUF MORTALITAT UND MORBIDITAT BEI PATIENTEN MIT LINKSVENTRIKULARER DYSFUNKTION NACH MYOKARDINFARKT. ERGEBNISSE DER 'SURVIVAL-AND-VENTRICULAR-ENLARGEMENT'-STUDIE (1992) (0)
Bone Marrow Cell Characteristics Associated with Patient Profile and Cardiac Performance Outcomes in the LateTIME-CCTRN Trial (2016) (0)
Is the Increasing Use of Smartphones Causing Stroke in Young Americans ? (2014) (0)
Applications of covariate adjusted nonparametric methods to CCTRN clinical trials (2022) (0)
Author Correction: Circulating Biomarkers to Identify Responders in Cardiac Cell therapy (2018) (0)
lcohol Consumption and Prognosis n Patients With Left Ventricular Systolic ysfunction After a Myocardial Infarction (2016) (0)
One-Sided Versus Two-Sided Testing (2006) (0)
Circulating Biomarkers to Identify Responders in Cardiac Cell therapy (2017) (0)
1356 FOUR METHODS OF EXPRESSING HUMAN MILK (1981) (0)
Abstract 16161: Bone Marrow Characteristics are Associated With Changes in Infarct Size Following STEMI: A Biorepository Evaluation From the CCTRN TIME Trial (2014) (0)
Prologue: “Let Others Thrash it out!” A Brief History (2000) (0)
1.P.146 Cholesterol reduction with pravastatin in CARE patients is beneficial irrespective of fasting glucose levels (1997) (0)
Loud Messengers — P Values and Effect Size (2000) (0)
Differences in sodium and nitrogen contents between preterm and term milk. (1980) (0)
A Hypothesis-Testing Primer (2006) (0)
Multiple Testing and Combined Endpoints (2006) (0)
Systolic hypertension in the elderly program (SHEP). IX, Behavioral characteristics (1991) (0)
Reduction of Stroke Incidence After Myocardial Infarction With Pravastatin The Cholesterol and Recurrent Events (CARE) Study Clinical Investigation and Reports (1998) (0)
Blind Guides for Explorers: P Values, Subgroups and Data Dredging (2000) (0)
Abstract 16663: Patient and Cell Characteristics Associated With Clinical Outcomes in the CCTRN LateTIME Trial (2014) (0)
Abstract 21129: Arterial Anatomy and Functional Performance in Peripheral Artery Disease: Cardiovascular Cell Therapy Research Network Patients With Intermittent Claudication Injected With ALDH Bright Cells: CCTRN PACE (2017) (0)
P -values and Regression Analyses (2006) (0)
Author Correction: Circulating Biomarkers to Identify Responders in Cardiac Cell therapy (2018) (0)
Effects of captopril on mortality and morbidity rates in patients with left ventricular dysfunction following myocardial infarction: Results of survival and ventricular hypertrophic studies (1993) (0)
From the Cardiovascular Cell Therapy Research Network Bone Marrow Mononuclear Cell Therapy for Acute Myocardial Infarction : A Perspective (2014) (0)
Response to McMahon and Lange (1993) (0)
62A Decision rules for predicting future lipid values in a cholesterol reduction clinical trial (1994) (0)
Reproducibility of Cardiac Magnetic Resonance Imaging in Patients With Cardiac Implantable Electrical Devices (2022) (0)
Optimal Allocation of Sample Sizes to Multicenter Clinical Trials (2013) (0)
Abstract 16882: Temporal Changes in the Peripheral Blood Mononuclear Cell Populations After Acute Myocardial Infarction and Prediction of Improvement in Left Ventricular Function in the Cardiovascular Cell Therapy Research Network (CCTRN) TIME and Late-TIME Trials (2018) (0)
Perils of the Random Experiment (2003) (0)
Mistaken Identity: P -values in Epidemiology (2006) (0)
Clinical Monitoring in a Federally Funded Environment: Evolution and Opportunities in the Cardiovascular Cell Therapy Research Network. (2014) (0)
Patients, Patience, and P Values (2000) (0)
Value of Early Adenosine Technetium-99 m estamibi Myocardial Perfusion Imaging n Identifying a Low-Risk Group for Early ospital Discharge After Acute Myocardial Infarction (2006) (0)
Search Versus Research (2006) (0)
Abstract 3477: Increase in Creatinine and Cardiovascular Risk in Patients with Systolic Dysfunction after Myocardial Infarction (2006) (0)
of randomized and cohort cell Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in Patients With Acute Myocardial Infarction Based on Individual Patient Data (2015) (0)
Rejoinder: The new adversary (2008) (0)
myocardial infarction Right ventricular dysfunction and risk of heart failure and mortality after (2011) (0)
Abstract 16572: Progenitor Cells of Hypertensive CAD Patients With Heart Failure: A Principal Component Analysis Sub-Study From the CCTRN FOCUS Trial (2017) (0)
IX, BEHAVIORAL CHARACTERISTICS (1991) (0)
Abstract 14931: Electromechanical Assessment of Myocardial Function is Associated With Improvement in Ejection Fraction in Patients Treated With Autologous Stem Cell Therapy for Ischemic Cardiomyopathy (2013) (0)
Scientific Reasoning, P -values, and the Court (2006) (0)
Abstract 16155: Identification of Clinical Factors in Cell Therapy Trials That Determine Recovery versus Deterioration of LV Function Following STEMI (2014) (0)
Neurons vs. Silicon: Regression Analysis and P values (2000) (0)
Sex bias in the management of coronary artery disease (1990) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Lemuel A. Iii Moyé?

Lemuel A. Iii Moyé is affiliated with the following schools:

Lemuel A. Iii Moyé's Academic­Influence.com Rankings

Why Is Lemuel A. Iii Moyé Influential?

Lemuel A. Iii Moyé's Published Works

Published Works

What Schools Are Affiliated With Lemuel A. Iii Moyé?

Lemuel A. Iii Moyé's AcademicInfluence.com Rankings